Apellis Pharmaceuticals, Inc. and its partner Swedish Orphan Biovitrum AB (Sobi) appear well positioned with their complement inhibitor pegcetacoplan to compete in a market for two rare kidney diseases that have no approved treatments – but could soon become competitive.
Apellis’s Pegcetacoplan Hits 'Grand Slam' Scenario In Rare Kidney Disease
A Phase III trial testing pegcetacoplan in patients with two rare kidney diseases demonstrated impressive efficacy, outperforming what Novartis showed with Fabhalta in a similar trial.
